



Dr. rer. nat. Björn Moosmann

Rechtsmedizin · Dept. IV

Kontakt

Dr. rer. nat. Björn Moosmann
Rorschacherstrasse 95
9007 St. Gallen

T +41 71 494 2163
Bjoern.Moosmann@kssg.ch

Orcid

0000-0003-1757-6359

Bereiche

Rechtsmedizin

Publikationen (12)

Bergerhoff M, Moosmann B. Novel Receptor–Binding–Based Assay for the Detection of Opioids in Human Urine Samples. *Anal Chem* 2023

Volz M, Moosmann B. Development of a non-radioactive mass spectrometry-based binding assay at the μ -opioid receptor and its application for the determination of the binding affinities of 17 opiates/opioids as well as of the designer opioid isotonitazene and five further 2-benzylbenzimidazoles. *Anal Chim Acta* 2022; 1219:339978.

Erdmann J, Moosmann B. Cross reactivity of the CEDIA and HEIA benzodiazepine kits for 29 designer benzodiazepines and tofisopam. *Drug Test Anal* 2021; 13:1686–1688.

Moosmann B. New psychoactive substances—Designer benzodiazepines. *WIREs Forensic Science* 2021; 3:1416–1439.

Kissling S, Blum S, Beyer J, Moosmann B, Hausmann R (2020). Verzögerter Todeseintritt nach Einnahme von Natrium-Pentobarbital. Präsentiert bei: DGRM Jahrestagung, Luzern

Moosmann B, Bisel P, Westphal F, Wilde M, Kempf J, Angerer V, Auwärter V. Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864). *Drug Test Anal* 2019; 11:541–549.

Angerer V, Franz F, Moosmann B, Bisel P, Auwärter V. 5F-Cumyl-PINACA in 'e-liquids' for electronic cigarettes: comprehensive characterization of a new type of synthetic cannabinoid in a trendy product including investigations on the in vitro and in vivo phase I metabolism of 5F-Cumyl-PINACA and its non-fluorinated analog Cumyl-PINACA. *Forensic Toxicol* 2018; 37:186–196.

Mogler L, Franz F, Wilde M, Huppertz L, Halter S, Angerer V, Moosmann B, Auwärter V. Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samples. *Drug Test Anal* 2018; 10:1417–1429.

Moosmann B, Auwärter V. Designer Benzodiazepines: Another Class of New Psychoactive Substances. In: *New Psychoactive Substances*. Springer, Cham, 2018. S. 383–410.

Mogler L, Moosmann B, Kassiou M, Banister S, Longworth M, Weinfurtner G, Angerer V, Rentsch D, Franz F, Auwärter V. Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples. *Drug Test Anal* 2017; 10:196–205.

Huppertz L, Moosmann B, Auwärter V. Flubromazolam – Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. *Drug Test Anal* 2017; 10:206–211.

Moosmann B. Pharmakologie und Toxikologie synthetischer Cannabinoidrezeptor-Agonisten. In: *Handbuch Psychoaktive Substanzen*. Heidelberg: Springer, 2016. S. 389–409.

Projekte (1)

Novel screening assay for novel psychoactive substances

Grundlagenforschung - 01.05.2024 - 30.04.2025

Geplant

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch